Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Tara C Gangadhar, MD

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Teaching Attending, Penn Internal Medicine Oncology inpatient rotation for residents, interns and medical students., University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-202
3400 Civic Center Blvd.
South Pavilion, 7th Floor
Philadelphia, PA 19104
Office: 215-662-7907
Fax: 215-662-4646
Education:
BA (Anthropology)
Columbia University, 2000.
MD (Internal Medicine)
New York University School of Medicine, 2004.
Post-Graduate Training
Intern in Internal Medicine, Indiana University Medical Center, 2004-2005.
Resident in Internal Medicine , Indiana University Medical Center, 2005-2007.
Fellow in Hematology/Oncology, The University of Chicago, 2007-2011.
Fellow in Clinical Pharmacology and Pharmacogenomics, The University of Chicago , 2009-2011.
Certifications
American Board of Internal Medicine (Internal Medicine), 2007.
American Board of Internal Medicine (Medical Oncology), 2010.
American Board of Clinical Pharmacology (Clinical Pharmacology), 2011.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Melanoma
Cutaneous malignancies

Description of Research Expertise

Melanoma
Immune therpay
Targeted therapy
Phase I trials
Combination therapy
Experimental therapeutics
Pharmacology

Selected Publications

Hodi F Stephen, Hwu Wen-Jen, Kefford Richard, Weber Jeffrey S, Daud Adil, Hamid Omid, Patnaik Amita, Ribas Antoni, Robert Caroline, Gangadhar Tara C, Joshua Anthony M, Hersey Peter, Dronca Roxana, Joseph Richard, Hille Darcy, Xue Dahai, Li Xiaoyun Nicole, Kang S Peter, Ebbinghaus Scot, Perrone Andrea, Wolchok Jedd D: Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34(13): 1510-7, May 2016.

Ribas Antoni, Hamid Omid, Daud Adil, Hodi F Stephen, Wolchok Jedd D, Kefford Richard, Joshua Anthony M, Patnaik Amita, Hwu Wen-Jen, Weber Jeffrey S, Gangadhar Tara C, Hersey Peter, Dronca Roxana, Joseph Richard W, Zarour Hassane, Chmielowski Bartosz, Lawrence Donald P, Algazi Alain, Rizvi Naiyer A, Hoffner Brianna, Mateus Christine, Gergich Kevin, Lindia Jill A, Giannotti Maxine, Li Xiaoyun Nicole, Ebbinghaus Scot, Kang S Peter, Robert Caroline: Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 315(15): 1600-9, Apr 2016.

Shannan Batool, Chen Quan, Watters Andrea, Perego Michela, Krepler Clemens, Thombre Rakhee, Li Ling, Rajan Geena, Peterson Scott, Gimotty Phyllis A, Wilson Melissa, Nathanson Katherine L, Gangadhar Tara C, Schuchter Lynn M, Weeraratna Ashani T, Herlyn Meenhard, Vultur Adina: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment cell & melanoma research 29(3): 317-28, Feb 2016.

Dizon Don S, Krilov Lada, Cohen Ezra, Gangadhar Tara, Ganz Patricia A, Hensing Thomas A, Hunger Stephen, Krishnamurthi Smitha S, Lassman Andrew B, Markham Merry Jennifer, Mayer Erica, Neuss Michael, Pal Sumanta Kumar, Richardson Lisa C, Schilsky Richard, Schwartz Gary K, Spriggs David R, Villalona-Calero Miguel Angel, Villani Gina, Masters Gregory: Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34(9): 987-1011, Feb 2016.

Ribas Antoni, Puzanov Igor, Dummer Reinhard, Schadendorf Dirk, Hamid Omid, Robert Caroline, Hodi F Stephen, Schachter Jacob, Pavlick Anna C, Lewis Karl D, Cranmer Lee D, Blank Christian U, O'Day Steven J, Ascierto Paolo A, Salama April K S, Margolin Kim A, Loquai Carmen, Eigentler Thomas K, Gangadhar Tara C, Carlino Matteo S, Agarwala Sanjiv S, Moschos Stergios J, Sosman Jeffrey A, Goldinger Simone M, Shapira-Frommer Ronnie, Gonzalez Rene, Kirkwood John M, Wolchok Jedd D, Eggermont Alexander, Li Xiaoyun Nicole, Zhou Wei, Zernhelt Adriane M, Lis Joy, Ebbinghaus Scot, Kang S Peter, Daud Adil: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology 16(8): 908-18, Aug 2015.

Twyman-Saint Victor Christina, Rech Andrew J, Maity Amit, Rengan Ramesh, Pauken Kristen E, Stelekati Erietta, Benci Joseph L, Xu Bihui, Dada Hannah, Odorizzi Pamela M, Herati Ramin S, Mansfield Kathleen D, Patsch Dana, Amaravadi Ravi K, Schuchter Lynn M, Ishwaran Hemant, Mick Rosemarie, Pryma Daniel A, Xu Xiaowei, Feldman Michael D, Gangadhar Tara C, Hahn Stephen M, Wherry E John, Vonderheide Robert H, Minn Andy J: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547): 373-7, Apr 2015.

Gangadhar Tara C, Schuchter Lynn M: Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. JAMA oncology 1(4): 427-8, Jul 2015.

Wang Tao, Xiao Min, Ge Yingbin, Krepler Clemens, Belser Eric, Lopez-Coral Alfonso, Xu Xiaowei, Zhang Gao, Azuma Rikka, Liu Qin, Liu Rui, Li Ling, Amaravadi Ravi K, Xu Wei, Karakousis Giorgos, Gangadhar Tara C, Schuchter Lynn M, Lieu Melissa, Khare Sanika, Halloran Molly B, Herlyn Meenhard, Kaufman Russel E: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical cancer research : an official journal of the American Association for Cancer Research 21(7): 1652-64, Apr 2015.

Robert Caroline, Ribas Antoni, Wolchok Jedd D, Hodi F Stephen, Hamid Omid, Kefford Richard, Weber Jeffrey S, Joshua Anthony M, Hwu Wen-Jen, Gangadhar Tara C, Patnaik Amita, Dronca Roxana, Zarour Hassane, Joseph Richard W, Boasberg Peter, Chmielowski Bartosz, Mateus Christine, Postow Michael A, Gergich Kevin, Elassaiss-Schaap Jeroen, Li Xiaoyun Nicole, Iannone Robert, Ebbinghaus Scot W, Kang S Peter, Daud Adil: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948): 1109-17, Sep 2014.

Hamid Omid, Robert Caroline, Daud Adil, Hodi F Stephen, Hwu Wen-Jen, Kefford Richard, Wolchok Jedd D, Hersey Peter, Joseph Richard W, Weber Jeffrey S, Dronca Roxana, Gangadhar Tara C, Patnaik Amita, Zarour Hassane, Joshua Anthony M, Gergich Kevin, Elassaiss-Schaap Jeroen, Algazi Alain, Mateus Christine, Boasberg Peter, Tumeh Paul C, Chmielowski Bartosz, Ebbinghaus Scot W, Li Xiaoyun Nicole, Kang S Peter, Ribas Antoni: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 369(2): 134-44, Jul 2013.

back to top
Last updated: 08/31/2016
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration